AZ launches branded YouTube channel, testimonial site

Share this article:

AstraZeneca (AZ) launched a branded YouTube channel today for its asthma drug Symbicort, as well as My Asthma Story (, a website calling for testimonial videos.

The YouTube channel and “vlog” (video blog) feature testimonial videos in widescreen, where patients describe their experiences with Symbicort. Some risk information scrolls across the bottom margin of the videos while they play, and a link to full PI information appears near the top of the channel page. Other fair balance information appears elsewhere on the page. The channel also directs consumers to, where Symbicort users are invited to upload videos about their own experiences with the drug.

According to Dana Settembrino, senior brand communications manager at AZ, the videos submitted on will be reviewed by a panel of legal, regulatory and compliance experts, with their selections appearing on the Symbicort YouTube channel.  Videos appearing on the YouTube channel are not open for comment by viewers.

The YouTube channel and the My Asthma Story website were created by Digitas and Cadient, and allow asthma-sufferers to “share patient stories about controlling asthma,” said Settembrino.  “[The channel and website] is a way to engage patients and maintain a conversation,” she said.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...